Armata Pharmaceuticals Debt 2024

Armata Pharmaceuticals Aktienanalyse

What does Armata Pharmaceuticals do?

Armata Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of therapies for severe bacterial infections. The company was founded in California in 2009 and has been listed on the NASDAQ stock exchange since 2019. The founders of Armata Pharmaceuticals Inc. recognized that antibiotic resistance is a growing problem and that it is crucial to develop new therapies to address the challenges in the fight against bacterial infections. The company's business model is based on the discovery and development of bacteriophage therapies. Bacteriophages are natural viruses that can infect and destroy bacteria. Armata Pharmaceuticals Inc. has two main divisions: Armatavax, which focuses on the development of vaccines against bacterial infections, and Armatamab, which works on the development of monoclonal antibodies that express bacteriophage genes and thus have higher efficacy in combating bacteria. The company is currently developing several products based on bacteriophage therapies. The main product is AR-301, a monoclonal antibody designed to treat Staphylococcus infections causing pneumonia. AR-301 is in phase IIb study and has shown promising results. The company also has several other products in the pipeline, including AR-105 against Pseudomonas aeruginosa infections, AR-201 against Acinetobacter baumannii infections, and AR-401 against Enterobacteriaceae infections. Armata Pharmaceuticals Inc. works closely with various academic institutions and research facilities to explore the potential of bacteriophage therapies and develop new products. The company has acquired a number of patents and intellectual property in this area. To bring its products to market, Armata Pharmaceuticals Inc. has formed strategic partnerships with various companies, including AmpliPhi Biosciences, the United States Department of Defense's Drug Agency (DTRA), and Synthetic Biologics. These partnerships enable the company to lower its development costs while increasing access to a broader market. In summary, Armata Pharmaceuticals Inc. is an innovative biopharmaceutical company specializing in the development of bacteriophage therapies for severe bacterial infections. The company has a strong pipeline of products in various stages of development and is actively working to improve its technology and strengthen its market position. Through its partnerships and commitment to cutting-edge research, Armata Pharmaceuticals Inc. ensures that it is well-positioned to address the challenges in the fight against antibiotic resistance. Armata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Armata Pharmaceuticals's Debt Structure

Armata Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Armata Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Armata Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Armata Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Armata Pharmaceuticals Stock

What is the debt of Armata Pharmaceuticals this year?

Armata Pharmaceuticals has a debt level of 68.78 USD this year.

What was the debt of Armata Pharmaceuticals compared to the previous year?

The debt of Armata Pharmaceuticals has increased by -563.19% compared to the previous year dropped.

What are the consequences of high debt for investors in Armata Pharmaceuticals?

High debt can pose a risk for investors of Armata Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Armata Pharmaceuticals?

Low debt means that Armata Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Armata Pharmaceuticals affect the company?

An increase in debt of Armata Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Armata Pharmaceuticals affect the company?

A reduction in debt of Armata Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Armata Pharmaceuticals?

Some factors that can influence the debt of Armata Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Armata Pharmaceuticals so important for investors?

The debts of Armata Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Armata Pharmaceuticals take to change the debt?

To change the debt, Armata Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Armata Pharmaceuticals pay?

Over the past 12 months, Armata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Armata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Armata Pharmaceuticals?

The current dividend yield of Armata Pharmaceuticals is .

When does Armata Pharmaceuticals pay dividends?

Armata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Armata Pharmaceuticals?

Armata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Armata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Armata Pharmaceuticals located?

Armata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Armata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Armata Pharmaceuticals from 6/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/25/2024.

When did Armata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/25/2024.

What was the dividend of Armata Pharmaceuticals in the year 2023?

In the year 2023, Armata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Armata Pharmaceuticals pay out the dividend?

The dividends of Armata Pharmaceuticals are distributed in USD.